



03-14-03
Practitioner's Docket No. MWH-0031US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stephen B. Liggett
Application No.: 09/936,499
I.A. Filing Date: March 10, 2000
I.A. No.: PCT/US00/06502

Group Art Unit: 1623
Examiner:

FOR: VARIATION IN DRUG RESPONSE RELATED TO
POLYMORPHISMS IN BETA 2-ADRENERGIC RECEPTOR

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

Enclosed herewith please find:

1. Identification of Time of Filing the Accompanying Information Disclosure Statement
2. Supplemental Information Disclosure Statement by Applicant Form PTO/SB/08B (1 page)
3. Copies of Listed References Accompanying this Statement (2-Total)
4. Self-addressed stamped postcard

It is believed that no fee is required, but if that is incorrect you are hereby authorized to debit Deposit Account No. 50-1293 for any deficiency

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*

(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on MARCH 12, 2003 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL553594959US addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Adam Gentile
(type or print name of person mailing paper)
Adam Gentile
Signature of person mailing

Date: March 12, 2003

Melodie W. Henderson
Signature of Practitioner

Reg. No.: 37,848
Tel. No.: 203-786-3421
Customer No.: 25106

Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900



Applicant's Docket No. MWH-0031US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stephen B. Liggett
Application No.: 09/936,499
I.A. Filing Date: March 10, 2000
I.A. No.: PCT/US00/06502

Group Art Unit No.: 1623
Examiner:

FOR: VARIATION IN DRUG RESPONSE RELATED TO
POLYMORPHISMS IN BETA 2-ADRENERGIC RECEPTOR

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

The supplemental information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last 37 C.F.R. section 1.97(b).

Each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made by Applicants, or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,
GENAISSANCE PHARMACEUTICALS, INC.

Date: March 12, 2003
Tel. No. 203-786-3421
Fax No. 203-776-2788
Registration No. 37,848
m.henderson@genaisance.com

By: Melodie W. Henderson
Melodie W. Henderson



25106

PATENT TRADEMARK OFFICE

PTO/SB/08B (02-03)

MAR 13 2003

Approved for use through 04/30/2003. OMB 0651-0031
U S Patent and Trademark Office; U S DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|-------------------------------|--------------------|
| Application Number | 09/936,499 |
| Filing Date | 09/12/2001 |
| First Named Inventor | Stephen B. Liggett |
| Art Unit | 1623 |
| Examiner Name | |
| Attorney Docket Number | MWH-0031US |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

RECEIVED
MAR 21 2003
TECH CENTER 1600/2000

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[†] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
|---------------------------|-----------------------------|--|----------------------|
| | CA | LIGGETT, S.B., "POLYMORPHISMS OF THE B2-ADRENERGIC RECEPTOR AND ASTHMA," Am J. Respir Crit Care Med., p. 5156-5162, (1997). | |
| | CB | TAN, SOONG, ET AL., "Association Between B2-Adrenoceptor Polymorphisms and Susceptibility to Bronchodilator Desensitisation in Moderately Severe Stable Asthmatics," The Lancet, p. 995-999, (1997). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 9.08. The information is required to obtain or retain a benefit by the public which is to file (and) by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.